Pharma Trend: Survey of innovation and sustainability in the pharmaceutical industry

Pharma Trend

Pharma Trend, the survey to measure innovativeness and sustainability in the pharmaceuticals sector, has been conducted on behalf of the journal Pharma Barometer annually since 2000. The data for the representative benchmark study are collected online. On the basis of these data the winners of the awards ‘The Golden Tablet®’ and ‘Most Innovative Product®’ are determined. In addition, the data from the benchmark study form the basis for creating the Pharma Trend Ranking “Best Pharma Companies”.

Are you interested in participating in the 22nd Pharma Trend 2021?  Contact us without obligation!

Pharma Award

The special thing about the award is the jury: the benefits of the medication are evaluated exclusively by doctors, pharmacist and patients, based on their experience of applying the treatments. The reasons that were decisive for the awarding of the winners (top 1-3) are compiled with the respective placements in report volumes, which can be obtained in the formats “Standard” and “Basic”. In the basic version, the report volume contains the information on the winners of the awards “The Golden Tablet” and “The Most Innovative Product” with reasons for the award as well as the assessment of the image and the sales force, including some data compared to the previous year. The standard report volume also contains the assessments of four other pharmaceutical companies with regard to 11 aspects: Marketing and sales quality, product and service quality, innovative strength, profitability, transparency, responsibility, ethical action, management quality and business success.

The winners (top 1-3) of the 2020 awards carries the following drugs:

  • Acarizax by ALK-Abelló (allergists)
  • Aimovig by Novartis (general practitioners)
  • Ajovy by Teva (general practitioners)
  • Almased by Almased (patients)
  • Artelac by Bausch & Lomb (patients)
  • Aspirin by Bayer (pharmacists, patients)
  • Berinert by CSL Behring (allergists)
  • Bepanthen by Bayer (patients)
  • Bexsero by GlaxoSmithKline (pediatricians)
  • Canephron by Bionorica (urologists)
  • DeflaGyn by Exeltis (gynecologists)
  • Dolormin by Johnson & Johnson (patients)
  • Dupixent by Sanofi (allergists, pediatricians)
  • Emgality by Lilly (general practitioners)
  • Entyvio by Takeda (gastroenterologists)
  • Erleada by Janssen-Cilag (urologists)
  • Firazyr by Takeda (allergists)
  • Hylo Comod/Dual/Dual Intense by Ursapharm (pharmacists, patients)
  • Ibrance by Pfizer (gynecologists, oncologists)
  • Influsplit tetra by GlaxoSmithKline (general practitioners)
  • Influvac tetra by Mylan (general practitioners)
  • Imbruvica by Janssen-Cilag (oncologists)
  • Inlyta by Pfizer (oncologists)
  • Itulazax by ALK-Abelló (allergists)
  • Jorveza by Dr. Falk Pharma (gastroenterologists)
  • Keytruda by MSD (oncologists, urologists)
  • Kuvan by Biomarin International Ltd. (pediatricians)
  • Kyleena by Jenapharm (gynecologists)
  • Lamzede by Chiesi (pediatricians)
  • Lynparza by AstraZeneca (oncologists)
  • Maxalt lingua by MSD (general practitioners)
  • Monuril by Zambon (urologists)
  • Moventig by Kyowa Kirin (pain therapists)
  • Movicol by Norgine (pain therapists)
  • Nubeqa by Bayer (urologists)
  • Opdivo by Bristol-Myers Squibb (oncologists)
  • Orthomol Immun by Orthomol (patients)
  • Palynziq by Biomarin (pediatricians)
  • Polivy by Roche (oncologists)
  • Privmelam by Apogepha (urologists)
  • Resolor by Takeda (pain therapists)
  • Rizmoic by Hexal (pain therapists)
  • Scabioral by Infectpharm (pediatricians)
  • Shingrix by GlaxoSmithKline (general practitioners)
  • Slenyto by Infectopharm (pediatricians)
  • spermidineLIFE by Infectopharm (pharmacists, patients)
  • Spinraza by Biogen (pediatricians)
  • Stelara by Janssen-Cilag (gastroenterologists)
  • Tagrisso by AstraZeneca (oncologists)
  • Takhzyro by Takeda (allergists)
  • Tecentriq by Roche (oncologists)
  • Thomapyrin Tension Duo by Sanofi (pharmacists, patients)
  • Vaxigrip tetra by Sanofi (general practitioners)
  • Venclyxto by AbbVie (oncologists)
  • Verzenios by Lilly (oncologists)
  • Vitrakvi by Bayer (oncologists)
  • Xeljanz by Pfizer (gastroenterologists)
  • Xolair by Novartis (allergists)
  • Zolgensma by Novartis (pediatricians, oncologists)
  • Zostavax by MSD (general practitioners)

Various communication packages are available for communicating the awards. For the winner in first place, the advertising label “The most innovative product” with details of the year, the respective specialist group and the addition “Top 1” is available. Winners on ranks 2 and 3 can use an advertising label with the addition “Top 3”. The rights of use of the advertising labels can be acquired for an unlimited time and place.

Interested? Contact us without obligation!

Pharma Ranking

The ranking is based on the holistic medical professionals’ evaluation of the pharmaceutical- and medical technology-companies concerning the following 11 aspects: quality of marketing and sales, quality of products and services, innovativeness, efficiency, transparency, accountability, ethical behavior, management quality and commercial success. At the same time, the respondents rate the companies according to reputation based on the criteria of overall impact, competence, reliability, credibility and recommendation. The ranking is calculated according to the importance of the 11 individual aspects for reputation using a statistical regression. It reliably reflects the detailed company assessment by doctors and pharmacists without being subject to arbitrary bias.

The complete ranking with all the companies assessed in the benchmark is compiled in report volumes, which can be obtained in the formats “Standard” and “Basic”. The Ranking Basis report volume contains the ranking of all companies included in the benchmark study. The Ranking Standard report volume also contains the data from the company’s benchmark for four other pharmaceutical companies with regard to the aforementioned 11 aspects.

The 2020 ranking includes (alphabetical order)

  • AbbVie
  • Alk-Abelló
  • Allergan
  • Allergopharma
  • Amgen
  • AstraZeneca
  • Bayer Vital / Jenapharm
  • Bencard
  • Bionorica
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Chiesi
  • Dr. Falk Pharma
  • Dr. Kade
  • Eli Lilly
  • Gedeon Richter
  • Gilead Sciences
  • GlaxoSmithKline
  • Grünenthal
  • Hexal
  • Infectopharm
  • Johnson and Johnson
  • MSD
  • Novartis Pharma
  • Novo Nordisk
  • Pfizer
  • Procter & Gamble
  • Roche
  • Sanofi / Sanofi Pasteur
  • Schwabe
  • Seqirus
  • Shire
  • Stallergenes Greer
  • Swedish Orphan Biovitrum
  • Takeda
  • Teva Pharmaceutical Industries / Ratiopharm
  • UCB

The companies placed in ranks 1 to 10 were announced in the context of the 21st “Pharma Trend Image & Innovation Award” For these companies, an advertising label is available according to the respective placement with details of the year and the additions “Top1”, “Top 5” and “Top 10”. The rights of use of the advertising labels can be acquired for an unlimited time and place.

Interested? Contact us without obligation!